<it>In vitro </it>cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against <it>Candida albicans</it>, human monocytic and kidney cell lines
<p>Abstract</p> <p>Background</p> <p>Invasive fungal infections such as candidiasis constitute an increasingly important medical problem. Drugs currently used for the treatment of candidiasis include polyenes (such as Amphotericin B) and azoles. Amphotericin B (AmpB) pr...
Main Authors: | Clement John G, Zhao Jinying, Wasan Ellen K, Gershkovich Pavel, Bartlett Karen, Lee Jinkyung, Leon Carlos G, Wasan Kishor M |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-08-01
|
Series: | Lipids in Health and Disease |
Subjects: | |
Online Access: | http://www.lipidworld.com/content/10/1/144 |
Similar Items
-
Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
by: Owen David, et al.
Published: (2011-08-01) -
A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.
by: Ellen K Wasan, et al.
Published: (2010-12-01) -
The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
by: Grace Cuddihy, et al.
Published: (2019-02-01) -
ICOS co-stimulation: friend or foe?
by: Jason Scott Stumhofer, et al.
Published: (2016-08-01) -
Comparative pharmacokinetics of amphotericin B after single- and multiple-dose administration of G-ABCD and conventional amphotericin B deoxycholate to rats
by: Huanhuan Qi, et al.
Published: (2020-09-01)